XOMA Royalty (XOMA) Income from Non-Controlling Interests (2024 - 2026)
XOMA Royalty (XOMA) reported Income from Non-Controlling Interests of $546000.0 for Q1 2026, up 430.1% on a YoY basis from $103000.0 in Q1 2025, and up 14.23% sequentially from $478000.0 in Q4 2025.
XOMA Royalty (XOMA) Income from Non-Controlling Interests (2024 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 3 years of Income from Non-Controlling Interests data on file, last reported at $546000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests rose 430.1% year-over-year to $546000.0; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (up 228.0% YoY), and the FY2025 full-year result was $840000.0, up 208.82% from the prior year.
- Income from Non-Controlling Interests rose to $546000.0 in Q1 2026, from $478000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $546000.0 in Q1 2026 to a low of $67000.0 in Q2 2024.
- A 3-year average of $214571.4 and a median of $103000.0 in 2024 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests soared 53.73% in 2025 and surged 430.1% in 2026, its largest moves.
- Tracing XOMA's Income from Non-Controlling Interests over 3 years: stood at $102000.0 in 2024, then surged by 368.63% to $478000.0 in 2025, then increased by 14.23% to $546000.0 in 2026.
- Business Quant data shows XOMA's Income from Non-Controlling Interests at $546000.0 in Q1 2026, $478000.0 in Q4 2025, and $103000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 546,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 546,000.00 |
| Dec 31, 2025 | 478,000.00 |
| Jun 30, 2025 | 103,000.00 |
| Mar 31, 2025 | 103,000.00 |
| Dec 31, 2024 | 102,000.00 |
| Sep 30, 2024 | 103,000.00 |
| Jun 30, 2024 | 67,000.00 |